NCT00744016View on ClinicalTrials.gov

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

October 31, 2007

Conditions
Ulcerative Colitis
Interventions
DRUG

Granulated mesalamine

0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning

DRUG

Placebo

Matching placebo capsules (4 capsules) were administered orally QD, in the morning

Trial Locations (1)

06010

Bristol

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00744016 - Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis | Biotech Hunter | Biotech Hunter